Don't miss the special BONUS offer during our Beta-test period. The next 100 new Registered Users (from a unique IP address), to post at least five (5) piglix, will receive 1,000 extra sign-up points (eventually exchangeable for crypto-currency)!

* * * * *    Free Launch Promotions    * * * * *

  • $2,000 in free prizes! is giving away ten (10) Meccano Erector sets, retail at $200 each, that build a motorized Ferris Wheel (or one of 22 other models) ... see details

  • Free Ads! if you are a business with annual revenues of less than $1M - will place your ads free of charge for up to one year! ... read more

Quality control in tissue engineering

The rapid development in the multidisciplinary field of tissue engineering has resulted in a variety of new and innovative medicinal products, often carrying living cells, intended to repair, regenerate or replace damaged human tissue. Tissue engineered medicinal products (TEMPs) vary in terms of the type and origin of cells and the product’s complexity. As all medicinal products, the safety and efficacy of TEMPs must be consistent throughout the manufacturing process. Quality control and assurance are of paramount importance and products are constantly assessed throughout the manufacturing process to ensure their safety, efficacy, consistency and reproducibility between batches. The European Medicines Agency (EMA) is responsible for the development, assessment and supervision of medicines in the EU. The appointed committees are involved in referral procedures concerning safety or the balance of benefit/risk of a medicinal product. In addition, the committees organize inspections with regards to the conditions under which medicinal products are being manufactured. For example, the compliance with good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) and pharmacovigilance (PhV).

When quality control of TEMPs is considered, a risk assessment needs to be conducted. A risk is defined as a “potentially unfavourable effect that can be attributed to the clinical use of advanced therapy medicinal products (ATMPs) and is of concern to the patient and/or to other populations (e.g. caregivers and off-spring)”. Some risks include immunogenicity, disease transmission, tumor formation, treatment failure, undesirable tissue formation, and inadvertent germ transduction. A risk factor is defined as a “qualitative or quantitative characteristic that contributes to a specific risk following handling and/or administration of an ATMP”. The integration of all available information on risks and risk factors is called risk profiling. Due to the fact that every TEMP is different, the risks associated with each one of them vary and, subsequently, the procedures that must be implemented to ensure its quality are also unique to the product. Once the risks associated with the TEMP are identified, the appropriate tests must be developed and validated accordingly. Thus, there is no standard set of tests for the quality control of TEMPs. The EMA has released a set of regulatory guidelines on the topics to be considered by companies involved in the development and marketing of medicines for use in the European Union. These guidelines have to be followed in order for the marketing authorization of a product to be issued. Fictitious examples of risk analysis for further elucidation of the process are provided in the EMA guidelines.



Don't forget! that as one of our early users, you are eligible to receive the 1,000 point bonus as soon as you have created five (5) acceptable piglix.